Magnetic quenching of positronium studied by positron annihilation lifetime and Doppler broadening measurements

Publication date: Available online 17 January 2020Source: Radiation Physics and ChemistryAuthor(s): J.D. Liu, J.Q. Guo, M. Luo, Z. Wang, H.J. Zhang, B.J. Ye, Z.Q. ChenAbstractAnnihilation of positronium (Ps) in static magnetic fields is investigated by positron annihilation lifetime (PAL) and Doppler broadening (DB) measurements of γ-Al2O3 nanopowder. The properties of four eigenstates of Ps atoms (|1,1〉, |1,−1〉, |+〉 (long-lived eigenstate mixed from |1,0〉 and |0,0〉 due to Zeeman effect), and |−〉 (short-lived eigenstate mixed from |1,0〉 and |0,0〉 due to Zeeman effect)) were revealed from PAL and DB results. Thereafter, with magnetic field increasing from 0.105 to 0.760 T, clear and regular variation of Ps annihilation parameters are observed: (1) The mean lifetime of the three long-lived Ps states (|1,1〉, |1,−1〉, and |+〉) shows clear quenching effect; (2) The formation probability of each Ps eigenstate (|1,1〉, |1,−1〉, |+〉, and |−〉) keeps unchanged; (3) The intensity of the narrow component (derived from multi-Gaussian fitting) of DB spectrum exhibits a gradual increase which is in good agreement with the theoretical calculation from PAL results (2γ decay of |+〉 and |−〉 states, and pick-off quenching of long-lived Ps states); (4) The intensity of the low energy region of DB spectrum is diminished by the decrease of 3γ decay of |+〉 state. The quantitative correlations between magnetic fi...
Source: Radiation Physics and Chemistry - Category: Physics Source Type: research

Related Links:

AbstractBackgroundPrevious studies have identified that patients withEGFR mutations tend to have better responses to targeted therapy, as well as chemotherapy; however, the effect of genetic alterations in terms of radiotherapy (RT) ‐related outcomes has not been fully assessed. We studied the impact of common non‐small cell lung cancer (NSCLC) genetic alterations (EGFR,ALK andKRAS) in relation to objective response rate (ORR) to RT in patients with brain metastases.MethodsFrom 2009 –2015, 153 patients with an available genotyping status were treated with whole‐brain irradiation (WBI) before receiving systemic ...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
ConclusionsEndostar delivered by CIV with CCRT may be a better option than IV in terms of potential survival and safety for unresectable stage III NSCLC.Key pointsSignificant findings of the study Endostar delivered by continuous intravenous pumping might achieve more favorable survival over intravenous injection and reduce adverse hematological reactions in patients with unresectable stage III NSCLC treated with Endostar combined with CCRT.What this study adds The administration route of recombinant human endostatin is also one key factor for survival and safety to consider when treating patients with unresectable stage III NSCLC.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
ConclusionsThe use of osimertinib immediately after nivolumab significantly increased the frequency of grade 3 or higher hepatotoxicity in patients with advanced NSCLC harboringEGFR mutation acquired T790M resistance.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Authors: Dietrich DE, Bode L, Spannhuth CW, Hecker H, Ludwig H, Emrich HM Abstract BACKGROUND: Whether Borna disease virus (BDV-1) is a human pathogen remained controversial until recent encephalitis cases showed BDV-1 infection could even be deadly. This called to mind previous evidence for an infectious contribution of BDV-1 to mental disorders. Pilot open trials suggested that BDV-1 infected depressed patients benefitted from antiviral therapy with a licensed drug (amantadine) which also tested sensitive in vitro. Here, we designed a double-blind placebo-controlled randomized clinical trial (RCT) which cross-lin...
Source: BMC Pharmacology and Toxicology - Category: Drugs & Pharmacology Tags: BMC Pharmacol Toxicol Source Type: research
Date: Friday, 02 28, 2020; Speaker: Jonathan Wasserman, Staff Physician, SickKids; BG 10-CRC; FAES 1&2
Source: NIH Calendar of Events - Category: American Health Source Type: events
Date: Tuesday, 03 03, 2020; Speaker: TBD, TBD; Dr. Jeremy Veenstra-VanderWeele, Columbia University; Building: Building 10 (Clinical Center); Lipsett Auditorium; CME Credit
Source: NIH Calendar of Events - Category: American Health Source Type: events
Date: Tuesday, 03 10, 2020; Speaker: TBD, TBD; Dr. Jeff Elias, University of Virginia School of Medicine; Building: Building 10 (Clinical Center); Lipsett Auditorium; CME Credit
Source: NIH Calendar of Events - Category: American Health Source Type: events
Date: Tuesday, 03 10, 2020; Speaker: Staff NIH Library; Building: Building 10 (Clinical Center); NIH Library Training Room
Source: NIH Calendar of Events - Category: American Health Source Type: events
Date: Wednesday, 03 11, 2020; Speaker: Staff NIH Library; Building: Building 10 (Clinical Center); This class is presented as a webinar only; Videocast Event
Source: NIH Calendar of Events - Category: American Health Source Type: events
Date: Thursday, 03 12, 2020; Speaker: BTRIS instructor; Building: Building 10 (Clinical Center); NIH Library Training Room
Source: NIH Calendar of Events - Category: American Health Source Type: events
More News: Chemistry | Nanotechnology | Physics